Hong Guan Ltd.

Beihao Stem Cell and Regenerative Medicine Research Institute Co., Ltd.

Newish Technology (beijing) Co., Ltd.

Newish Technology Co., Ltd.

Defang Liu

Jing Li

Weiwei Li

Hongkui Deng

Xiaofang Wang

Hailong Qi

Zhongjie Sun

Huangfan Xie

Xiaomin Du

Yantao Ma

Xiao E Yan

Ligong Chen

The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.

Composition for treating cancer and use and medicament thereof

Provided are chemical inducers of lineage reprogramming (CiLR) which include glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, cyclic AMP agonists or histone acetylators. Also provided is a method of inducing lineage reprograming in a partially or completely differentiated cell of a first type into a cell with characteristics of a second and different lineage. The method includes: contacting a cell with the CiLR for a sufficient period of time to result in reprograming the cell into a modified XEN-like cell which is subsequently programmed into a cell with characteristics of a second and different lineage.

Methods for chemically induced lineage reprogramming

Growing community of inventors

Beijing, China

Defang Liu